Perspective on Antiarrhythmic Drug Combinations

被引:3
|
作者
Reiffel, James A. [1 ]
Robinson, Victoria M. [2 ,3 ]
Kowey, Peter R. [4 ]
机构
[1] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY 10032 USA
[2] Lankenau Heart Inst, Wynnewood, PA USA
[3] Thomas Jefferson Univ, Philadelphia, PA USA
[4] Univ Manchester, Div Cardiovasc Sci, Manchester, England
来源
关键词
ATRIAL-FIBRILLATION; CLASS-IA; VENTRICULAR-TACHYCARDIA; QUINIDINE MONOTHERAPY; THERAPY; MEXILETINE; RANOLAZINE; AMIODARONE; DRONEDARONE; AGENTS;
D O I
10.1016/j.amjcard.2023.01.035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Physicians use multiple drugs in combination to treat hypertension, heart failure, diabetes tors. However, administering antiarrhythmic drugs (AAD) in combination is rarely discussed. Yet, the possibility of increasing efficacy and/or tolerance and/or safety of AADs Unfortunately, this topic has not been reviewed in any contemporary cardiac literature of which we are aware, although information regarding AAD combinations has been published. In conclusion, and accordingly, this review discusses the possibility of using AAD combinations for both ventricular arrhythmias and atrial fibrillation, in which the rationale for such combinations, considerations for such combinations, and supporting literature are covered. (c) 2023 Elsevier Inc. All rights reserved. (Am J Cardiol 2023;192:116 -123)
引用
下载
收藏
页码:116 / 123
页数:8
相关论文
共 50 条